Eighteen cancer treatments publicly funded across the ditch are not available to New Zealanders, despite offering “substantial” clinical benefit, new analysis has found.
Te Aho o Te Kahu, the Cancer Control Agency, on Thursday released a report comparing the availability of cancer medicines in Aotearoa and Australia, in terms of quantity and clinical benefit.
It identified 20 different gaps (18 individual medicines) – where a cancer medicine was funded in Australia but not in New Zealand – across nine cancer types.
